Physician profile
Mark Turrill
NPI 1568542314
$1,852.29
in general payments reported to CMS, 2019-2025
25 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $243 · 2021: $457 · 2022: $264 · 2023: $259 · 2024: $262 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.06 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $276.52 | 2019-2025 | |
| Celgene Corporation | $235.72 | 2019-2025 | Reblozyl, Opdivo |
| Merck Sharp & Dohme LLC | $190.01 | 2019-2023 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $156.61 | 2020-2023 | Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $110.33 | 2019-2023 | Opdivo |
| Alexion Pharmaceuticals, INC. | $99.00 | 2020-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $98.48 | 2021-2025 | Ojjaara |
| Genentech USA, INC. | $91.56 | 2019-2021 | |
| Janssen Biotech, INC. | $72.57 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $72.54 | 2020-2024 | Imfinzi, Enhertu |
| Amgen INC. | $69.41 | 2019-2021 | |
| Astellas Pharma US INC | $54.86 | 2021-2022 | |
| Incyte Corporation | $47.00 | 2020-2021 | |
| Abbvie INC. | $33.31 | 2020-2022 | |
| Acrotech Biopharma INC. | $33.14 | 2021-2025 | Beleodaq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $27.56 | 2024 | Evoke |
| Rigel Pharmaceuticals, INC. | $23.97 | 2024 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $23.93 | 2024 | |
| Gilead Sciences, INC. | $23.04 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $21.94 | 2021 | |
| Kyowa Kirin, INC. | $20.20 | 2023 | Poteligeo |
| Seagen INC. | $18.56 | 2019 | |
| Tersera Therapeutics LLC | $18.39 | 2025 | Zoladex |
| Eisai INC. | $18.18 | 2023 | |
| Array Biopharma INC | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Turrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.